JGC
CYTK icon

J. Goldman & Co’s Cytokinetics CYTK Stock Holding History

J. Goldman & Co’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,600
Closed -$864K – 710
2025
Q4 		$864K Buy
+13,600
New +$846K 0.02% 404

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Goldman & Co's CYTK Position: Q2 2026 in Review

J. Goldman & Co increased its Cytokinetics (CYTK) stake by 50% in Q2 2026, buying an estimated $430K and bringing the position to 18,002 shares worth $1.53M. The position accounts for 0.04% of the portfolio, ranked #392.

J. Goldman & Co first reported a position in CYTK in Q1 2023 and has held it in 9 quarters since. The position peaked at $3.72M in Q1 2023. 484 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • J. Goldman & Co held 18,002 shares of Cytokinetics worth $1.53M as of Q2 2026.
  • J. Goldman & Co bought 5,995 Cytokinetics shares in Q2 2026, an estimated $430K.
  • Cytokinetics made up 0.04% of J. Goldman & Co's portfolio in Q2 2026, its #392 holding.
  • J. Goldman & Co first reported a position in Cytokinetics in Q1 2023 and has held it in 9 quarters since.
  • J. Goldman & Co's Cytokinetics position peaked at $3.72M in Q1 2023.
  • 484 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.